0001013762-16-001535.txt : 20160503 0001013762-16-001535.hdr.sgml : 20160503 20160503165958 ACCESSION NUMBER: 0001013762-16-001535 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160429 FILED AS OF DATE: 20160503 DATE AS OF CHANGE: 20160503 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DelMar Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001498382 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 990360497 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: SUITE 720-999 WEST BROADWAY CITY: VANCOUVER STATE: A1 ZIP: V5Z 1K5 BUSINESS PHONE: (604) 629-5989 MAIL ADDRESS: STREET 1: SUITE 720-999 WEST BROADWAY CITY: VANCOUVER STATE: A1 ZIP: V5Z 1K5 FORMER COMPANY: FORMER CONFORMED NAME: Berry Only Inc. DATE OF NAME CHANGE: 20100805 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brown Dennis M CENTRAL INDEX KEY: 0001569520 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-54801 FILM NUMBER: 161616235 MAIL ADDRESS: STREET 1: 100 SAN MATEO DR CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 f4042916brown_delmar.xml OWNERSHIP DOCUMENT X0306 4 2016-04-29 0 0001498382 DelMar Pharmaceuticals, Inc. DMPI 0001569520 Brown Dennis M SUITE 720-999 WEST BROADWAY VANCOUVER A1 V5Z 1K5 BRITISH COLUMBIA, CANADA 1 1 0 0 Chief Scientific Officer Series B Preferred Stock 2016-04-29 4 P 0 3000 8.00 A 2016-04-29 Common Stock 30000 3000 D The Series B Preferred stock is convertible into such number of shares of common stock equal to the number of Preferred Shares to be converted, multiplied by the Stated Value of $8.00, divided by the Conversion Price in effect at the time of the conversion (the initial Conversion Price will be $0.80, subject to adjustment in the event of stock splits, stock dividends, and similar transactions). The Reporting Person purchased Series B Preferred Stock from the Company in a private placement on April 29, 2016 (the "Private Placement"). The Series B Preferred Stock will automatically convert to common stock at the earlier of (a) the Company's lead product candidate, VAL-083, receiving Food and Drug Administration or European Medicines Agency approval (provided that, at the time of such approval, the closing bid price of the common stock is at least $2.00 (subject to adjustment for stock splits or stock dividends) or (b) five years from the final closing of the Private Placement. /s/ Dennis Brown 2016-05-02